NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

AROVELLA THERAPEUTICS LIMITED (ALA)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
AROVELLA THERAPEUTICS LIMITED25/10/2021
SUDA PHARMACEUTICALS LTD05/12/201725/10/2021
SUDA LTD07/12/201205/12/2017
EASTLAND MEDICAL SYSTEMS LTD07/12/2012

Shareholder links

Our website ranking of ALA: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000182784
Address: Corporate Once, 84 Hotham Road, Preston, VIC 3072 Australia
Tel:  +61 8 6142 5555Fax: +61 8 9443 8858

Date first listed: 24/01/2002
Company Secretary: Tim Luscombe
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Developer, manufacturer and supplier of medical devices, particularly injection, infusion and blood-drawing devices

News & Events

Expand this box to read and print

The suspension of trading in the securities of Arovella Therapeutics Limited will be lifted immediately, following the release by ALA of an announcement in relation to a proposed in-licensing agreement.

12/10/2023

Arovella has entered into a global, exclusive license with Sparx Group to develop a world-first iNKT cell therapy targeting a validated target, Claudin 18.2 (CLDN18.2), which is expressed in gastric cancers, gastroesophageal junction cancers and pancreatic cancer. Equity-based upfront licencing fee and future stage-gated fees with industry-standard milestone payments in cash and equity. Licensed technology is based on Sparx's Phase 1 ready CLDN18.2 antibody, SPX-101, which has shown to outperform zolbetuximab in internal preclinical studies, and has an open IND with the FDA. Zolbetuximab is expected to be the first CLDN18.2-targeting therapy available for GC/GEJC, with FDA approval expected in January 2024. The intellectual property has long-life, is granted in the US and has been filed in other major territories worldwide (inc. Europe, Japan, China and South Korea). Arovella's CLDN18.2-iNKT cells will be the only off-the-shelf CAR-iNKT cell therapy being developed for this target and will significantly increase the value of Arovella's pipeline. CLDN18.2-iNKT cells with direct cancer-killing ability are expected to provide superior cancer killing properties relative to an antibody alone. Arovella's potential market for an FDA approved CLDN18.2-targeting product is supported by Astellas' forecast peak annual sales for zolbetuximab which are US$0.6-1.3 billion. Arovella's CEO and MD Dr Michael Baker will host an investor webinar discussing this announcement at 11am AEDT on Thursday 12 October.

12/10/2023

The securities of Arovella Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ALA, pending the release of an announcement in relation to a proposed inlicense agreement.

11/10/2023

name changed from Suda Pharmaceuticals Ltd

25/10/2021

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    15/12/2021Michael Baker650,000$0.039$25,350
    15/12/2021Paul Hopper1,000,000$0.040$40,000
    10/11/2020Paul Hopper234,669$0.039$9,152
    05/11/2020David Simmonds250,000$0.040$10,000
    27/10/2020Michael Baker400,000$0.042$16,800

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Thomas DuthyNon Exec Chairman13/03/2023
    Nicole van der WeerdenCOO04/01/2023
    Tim LuscombeCFO01/12/2023
    Gary PhillipsIndependent Director01/07/2022
    Elizabeth StonerNon Exec Director10/11/2021
    Debora BartonNon Exec Director12/08/2021
    Michael BakerExecutive Director, CEO02/01/2020

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Phillip HainsCFO01/07/202001/12/2023
    David SimmondsNon Exec Director27/03/201910/11/2023
    Paul HopperNon Exec Chairman15/05/201930/06/2022
    David PhillipsExecutive Director06/04/201814/01/2022
    Joseph OhayonCFO01/07/201030/09/2020
    Stephen CarterManaging Director, CEO26/10/201023/09/2019
    Michael StewartNon Exec Chairman11/06/200910/04/2018
    Ken RobsonNon Exec Director08/03/201307/08/2014
    Peter JoosteNon Exec Chairman03/07/200630/11/2012

    Date of first appointment, title may have changed.